This Week’s CGT News: Mapping the Scars of DNA Repair Processes
October 8, 2025
Our latest news roundup reports on grants for stem cell R&D, manufacturing and robotics partnerships, new products from Lonza, and more
4 min read
False
Advertisement
Industry News
FDA Sets Science Agenda for Generics: Priorities for 2026
October 3, 2025
The FDA has unveiled its top science and research priorities for FY 2026 under the GDUFA program, including nitrosamine risk, complex drug development, bioequivalence innovations, and the use of AI and modeling to modernize generics regulation...
2 min read
This Week’s Biopharma News: Emma Walmsley to Leave Role as GSK CEO
September 30, 2025
This week’s news roundup reports on GSK’s leadership change, a gene editing lawsuit facing AstraZeneca, Amgen’s Puerto Rico investment, and more
4 min read
Robust Efficacy in Regeneron Phase III Autoimmune Trial
September 26, 2025
Company plans to submit siRNA drug for regulatory approval in 2026
2 min read
This Week’s Biopharma News: Phase III Trial for Parkinson’s Disease Cell Therapy
September 24, 2025
Our latest news roundup reports on new guidelines in Europe, Pfizer’s acquisition of Metsera, and funding for better pharmaceutical catalysts.
5 min read
Preparing for CPHI 2025 in Frankfurt
September 23, 2025
Our interview with Tara Dougal offers a snapshot of what to expect at the event.
This Week’s Biopharma News: FDA to Release Complete Response Letters in Real Time
September 10, 2025
Our latest news roundup reports on Novartis’ proposed acquisition of Tourmaline Bio, GLP-1s being added to WHO’s lists of essential medicines, and new safety switches for cell and gene therapies.
3 min read
Tightened Surveillance: Inside the FDA’s Quality Enforcement Report
September 9, 2025
A surge in inspections, a spike in warning letters, and targeted action against high-risk sectors: the FDA’s 2024 report shows global pharma quality is under sharper scrutiny than ever.
4 min read
Rotavirus Co-Inventor Removed From FDA Vaccine Committee
By Stephanie Vine
September 4, 2025
Paul Offit, a longtime FDA advisor and prominent figure in vaccine development, sidelined from vaccine committee amid healthcare turmoil in the US.
2 min read
Regulators Sound Alarm on Dangers of Unapproved and Illicit GLP-1 Drugs
September 4, 2025
Increasing demand for GLP-1s sparks surge in illegal distribution
2 min read
